Patricia Mendez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Patricia Mendez has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Eric F. Donaldson
US Food and Drug Administration, Silver Spring MD 20993, United States of America
2 shared publications - Eric Hughes
Novartis Pharma, Basel, Switzerland (E.A.H.).
2 shared publications Poonam Mishra
Division of Antivirals, Center for Drug Evaluation and Research, US Food and Drug Administration , Silver Spring, Maryland , USA
2 shared publications- Veronica Miller
Forum for Collaborative Research, Washington DC; University of California Berkeley School of Public Health, Berkeley, USA
2 shared publications A. Ahmad
1 shared publicationA. Thiry
1 shared publication
Latest Publications
- Open Access
- 26 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (4) , 983-990
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
- 26 August 2023
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 78 (4) , 983-990
Open AccessChronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes
Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
- Open Access
- 5 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 525-538
Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection
- 5 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (2) , 525-538
Open AccessImmunological biomarker discovery in cure regimens for chronic hepatitis B virus infection
- 18 December 2015
- Published by Wiley in Liver International
- Vol. 36 (7) , 954-962
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
Background & Aims: We compared outcomes by cirrhosis status across studies of the all‐oral combination of daclatasvir (DCV) plus asunaprevir (ASV).Methods: Outcomes from global and Japanese phase 2 and 3 clinical studies of DCV+ASV in patients with genotype (GT) 1b infection were assessed by cirrhosis status. Sustained virological response (SVR) was assessed in individual phase 3 studies; a pooled analysis was carried out for safety outcomes.Results: In the Japanese phase 3 study, SVR12 was achieved by 91% of patients with cirrhosis (n = 22) and 84% of patients without cirrhosis (n = 200); in the global phase 3 study, SVR12 was achieved by 84% of patients with cirrhosis (n = 206) and by 85% of patients without cirrhosis (n = 437). The frequency of serious adverse events, adverse events leading to treatment discontinuation and treatment‐emergent grade 3/4 laboratory abnormalities was low (n = 229) or without (n = 689) compensated cirrhosis receiving DCV+ASV. Grade 3/4 reductions in platelets and neutrophils were more common among patients with cirrhosis (1.3 and 2.2%, respectively) compared with those without cirrhosis (both 0.6%). Grade 3/4 liver function test abnormalities were less common among patients with cirrhosis (1.8%) compared with those without cirrhosis (3.5–4.7%). Alanine aminotransferase elevations were not associated with hepatic decompensation.Conclusions: The safety and efficacy of DCV+ASV were similar in patients with or without compensated cirrhosis. This all‐oral, interferon‐ and ribavirin‐free combination is an effective and well‐tolerated treatment option for patients with HCV GT1b infection and cirrhosis.Trial registrations numbers: Clinicaltrials.gov identifiers: NCT01012895; NCT01051414; NCT01581203; NCT01497834.
- 18 December 2015
- Published by Wiley in Liver International
- Vol. 36 (7) , 954-962
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis
Background & Aims: We compared outcomes by cirrhosis status across studies of the all‐oral combination of daclatasvir (DCV) plus asunaprevir (ASV).Methods: Outcomes from global and Japanese phase 2 and 3 clinical studies of DCV+ASV in patients with genotype (GT) 1b infection were assessed by cirrhosis status. Sustained virological response (SVR) was assessed in individual phase 3 studies; a pooled analysis was carried out for safety outcomes.Results: In the Japanese phase 3 study, SVR12 was achieved by 91% of patients with cirrhosis (n = 22) and 84% of patients without cirrhosis (n = 200); in the global phase 3 study, SVR12 was achieved by 84% of patients with cirrhosis (n = 206) and by 85% of patients without cirrhosis (n = 437). The frequency of serious adverse events, adverse events leading to treatment discontinuation and treatment‐emergent grade 3/4 laboratory abnormalities was low (n = 229) or without (n = 689) compensated cirrhosis receiving DCV+ASV. Grade 3/4 reductions in platelets and neutrophils were more common among patients with cirrhosis (1.3 and 2.2%, respectively) compared with those without cirrhosis (both 0.6%). Grade 3/4 liver function test abnormalities were less common among patients with cirrhosis (1.8%) compared with those without cirrhosis (3.5–4.7%). Alanine aminotransferase elevations were not associated with hepatic decompensation.Conclusions: The safety and efficacy of DCV+ASV were similar in patients with or without compensated cirrhosis. This all‐oral, interferon‐ and ribavirin‐free combination is an effective and well‐tolerated treatment option for patients with HCV GT1b infection and cirrhosis.Trial registrations numbers: Clinicaltrials.gov identifiers: NCT01012895; NCT01051414; NCT01581203; NCT01497834.